Table 1 FDA approved antibody-drug conjugates for B cell malignancies and multiple myeloma
From: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
ADC names | Target | Indications | Dosage and schedule | Year of approval |
|---|---|---|---|---|
Brentuximab vedotin (Adcetrix®) | CD30 | R/R HL | - 1.8 mg/kg (maximum 180 mg) - Every 3 weeks until disease progression or unacceptable toxicity | 2011 |
Frontline stage III & IV HL (+ AVD) | - 1.2 mg/kg (maximum 120 mg) combined with chemotherapy - Every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity | 2018 | ||
Post-ASCT consolidation for HL | - 1.8 mg/kg (maximum 180 mg) - Initiate within 4–6 weeks post-ASCT or upon recovery from ASCT - Every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity | 2015 | ||
R/R systemic ALCL | - 1.8 mg/kg (maximum 180 mg) - Every 3 weeks until disease progression or unacceptable toxicity | 2011 | ||
R/R PTCL (+ CHP) | - 1.8 mg/kg (maximum 180 mg) combined with chemotherapy - Every 3 weeks with each cycle of chemotherapy for 6 to 8 doses | 2018 | ||
R/R CTCL | - 1.8 mg/kg (maximum 180 mg) - Every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity | 2017 | ||
Inotuzumab ozogamicin (Besponsa®) | CD22 | R/R B-cell ALL | - Cycle 1 (21 day-cycle): 1.8 mg/m2 [day 1 (0.8 mg/m2), day 8 (0.5 mg/m2), and day 15 (0.5 mg/m2)] - Subsequent cycles (28 day-cycle): 1) Patients who have achieved CR or CRi: 1.5 mg/m2 [day 1 (0.5 mg/m2), day 8 (0.5 mg/m2), and day 15 (0.5 mg/m2)] per cycle 2) Patients who have not achieved CR or CRi: repeat cycle 1 - Duration: 1) Patients proceeding to ASCT: 2 cycles 2) Patients not proceeding to ASCT: maximum 6 cycles | 2017 |
Moxetumomab pasudotox (Lumoxiti®) | CD22 | R/R HCL | - 0.04 mg/kg on days 1, 3, and 5 of each 28-day cycle. - Maximum of 6 cycles, disease progression, or unacceptable toxicity | 2018 |
Polatuzumab vedotin (Polivy®) | CD79b | R/R DLBCL (+ BR) | - 1.8 mg/kg per cycle, combined with BR - every 21 days for 6 cycles | 2019 |